Trinity Biotech has received approximately $7 million in additional investment from Perceptive Advisors to bolster its strategic growth initiatives, including its CGM+ continuous glucose monitoring platform and the Trinovium subsidiary focused on advanced cooling solutions. The company has also regained compliance with Nasdaq’s minimum bid price requirement, a positive step as it continues its operational transformation. CEO John Gillard emphasized the importance of these developments, highlighting the ongoing strategic repositioning aimed at leveraging advances in technology and forming partnerships in the diagnostics and diabetes management sectors.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/08/14/tmt-newswire/globenewswire/trinity-biotech-secures-additional-70-million-investment-from-perceptive-advisors-and-regains-compliance-with-nasdaq-minimum-bid-price-requirement/2405848
